Boat Oak Mossy Light Camouflage Grass Shadow MOM521002-Pin Base Boat Electrical & Lighting


  1. Home
  2. Boat Oak Mossy Light Camouflage Grass Shadow MOM521002-Pin Base
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Mossy Oak Boat Light Base MOM521002-Pin Shadow Grass Camouflage
Condition: New UPC:

039364989584

Country/Region of Manufacture: Taiwan Size: 2-pin
Manufacturer Part Number:

MOM52100

Color:

Camouflage

Boat Brand Part Number: MOM52100 Brand:

Mossy Oak Marine

Main Color: Camouflage MPN:

MOM52100

Type: Light Base Part Brand: Mossy Oak Marine



published on tue nov 09 2021

Boat Oak Mossy Light Camouflage Grass Shadow MOM521002-Pin Base Boat Electrical & Lighting

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Boat Oak Mossy Light Camouflage Grass Shadow MOM521002-Pin Base Boat Electrical & Lighting

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS